Full-Time

Validation Engineer III

Updated on 5/2/2025

Revance

Revance

501-1,000 employees

Biotechnology company for aesthetic solutions

Compensation Overview

$102.5k - $140.9k/yr

+ Annual Performance Bonus

Mid, Senior

Newark, CA, USA

Category
QA & Testing
Quality Assurance
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Revance referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Master’s degree & 2 years of directly related experience; OR
  • Bachelor’s degree & 4 years of directly related experience; OR
  • Associate's degree & 6 years of directly related experience.
Responsibilities
  • Design, execute, and/or coordinate commissioning, qualification, and validation activities as it relates to GxP Facilities, Utilities, Equipment, Cleaning, and Processes in accordance with company policies and US and international regulatory requirements.
  • Support the Re-validation Program through scheduling, tracking, and execution of validation and periodic review activities to maintain the validated state of GxP Facilities, Utilities, Equipment, Instruments, Cleaning and Processes.
  • Author, review and/or approve Validation Plans, Protocols, Specifications, Assessments and Reports.
  • Authors and/or implements changes to controlled documents (e.g., Standard Operating Procedures, Work Instructions, Specifications, Methods, etc.) as needed.
  • Own and process Quality Events (Deviations, Change Controls, and Corrective and Preventative Actions) for GxP Facilities, Utilities, Equipment, Instruments, Cleaning and Processes.
  • Manage and coordinate the activities of assigned validation and contract personnel to ensure the quality of completed work.
  • Provide technical expertise and interpretation on regulations and guidelines as they relate to validation activities.
  • Support the development, collection, and management of program metrics and key performance indicators to optimize performance, productivity, and effective resource planning.
  • Other duties as assigned.
Desired Qualifications
  • Bachelor’s degree or equivalent in biology, chemistry or related science, or equivalent experience.
  • Minimum 5 years' GxP experience in pharmaceutical and/or biotech related fields.
  • Working knowledge of quality systems cGMP standards applicable to biologic products.
  • Knowledge of GAMP validation principles, manufacturing processes and quality systems.
  • Knowledge of validation requirements (ISPE, FDA, etc.) for biopharmaceutical manufacturing facilities, equipment and systems.
  • Works under moderate supervision.
  • Ability to independently analyze and reconcile simple issues.
  • Ability to organize and manage multiple tasks in a fast-paced environment, with minimal instruction on routine work and moderate instructions on new assignments.
  • Excellent verbal and written communication and interpersonal skills.
  • Proficient with commonly used word processing, database systems, and other software.

Revance Therapeutics, Inc. specializes in aesthetic and therapeutic solutions, primarily focusing on products that enhance physical appearance and improve patient outcomes. The company offers neuromodulators, like botulinum toxin type A, which reduce wrinkles and treat muscle movement disorders, and dermal fillers that restore volume and smooth facial lines. Revance is also exploring therapeutic uses for its products in treating muscle movement and pain disorders. Additionally, the company has expanded into the fintech sector with the acquisition of HintMD, a platform that streamlines payment processes for aesthetic practices. This integration allows Revance to provide a comprehensive suite of services to support aesthetic practitioners. Unlike its competitors, Revance emphasizes differentiated products and improved patient experiences, aiming to establish itself as a leader in the premium aesthetics market.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in minimally invasive procedures benefits Revance's aesthetic product offerings.
  • Fintech integration in aesthetics enhances customer satisfaction and retention for Revance.
  • Global botulinum toxin market growth supports Revance's neuromodulator product expansion.

What critics are saying

  • Evolus's Jeuveau targets younger demographics, potentially capturing Revance's market share.
  • Class action lawsuit poses financial liabilities and reputational damage to Revance.
  • Minimum purchase obligations under Distribution Agreement present financial risks for Revance.

What makes Revance unique

  • Revance integrates fintech solutions like HintMD to streamline aesthetic practice payments.
  • The company focuses on innovative neuromodulators and dermal fillers for aesthetic treatments.
  • Revance targets personalized medicine trends with differentiated dermatology and aesthetic products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

401(k) Company Match

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

0%
Finimize
Mar 5th, 2025
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment

Evolus has strategically targeted a younger audience with its wrinkle treatment Jeuveau, setting itself apart from competitors like Revance and AbbVie, which usually focus on clients in their 40s.

GlobeNewswire
Feb 4th, 2025
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of "a material breach by the other party."

PR Newswire
Jan 31st, 2025
Revance Stockholders Urged To Tender Their Shares In Support Of Crown Transaction By The February 4Th Deadline

Crown offer of $3.65 per share is the only offer available to Revance stockholders. Crown offer unanimously approved by the Revance Board of Directors. Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender

Bizjournals
Jan 30th, 2025
Revance Therapeutics to Go Private at $3.65

Revance Therapeutics is set to go private with Crown Laboratories by Feb. 6. Crown has increased its offer to $3.65 per share, a 17% rise from the previous $3.10 offer. The deal, endorsed by Revance's board, is the only fully-financed offer available. The initial $6.66 offer was paused due to a breach with Teoxane, but a settlement has been reached. Revance's shares were trading at $3.63, with a 52-week range of $2.30-$7.56. The offer is valid until Feb. 4.

Teknovation
Jan 27th, 2025
News & Notes | Acting Administrator Of National Nuclear Security Administration Has Oak Ridge Ties

From Washington, DC but with Oak Ridge ties: Teresa Robbins has been named as the Acting Administrator of the National Nuclear Security Administration (NNSA). Prior to this, she served as... The post News Notes | Acting Administrator of National Nuclear Security Administration has Oak Ridge ties appeared first on Teknovation.biz.